GlassScriptPhysician profile
Robert J Isaak
NPI 1619197464
$3,108.91
in general payments reported to CMS, 2019-2025
15 companies · $228 in 2025
The $228 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $95.98 · 2020: $2,344 · 2021: $65.62 · 2022: $209 · 2023: $165 · 2025: $228.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $393.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $393.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Isoray, INC | $2,311.76 | 2020-2021 | |
| Novocure INC. | $152.79 | 2019-2025 | Optune Lua (Novottf-200t) |
| Bayer Healthcare Pharmaceuticals INC. | $137.33 | 2025 | |
| Janssen Biotech, INC. | $113.64 | 2023 | Erleada |
| Gt Medical Technologies, INC | $108.35 | 2022 | |
| Tolmar Pharmaceuticals, INC. | $70.57 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $50.33 | 2019-2023 | |
| Legend Biotech USA INC. | $31.63 | 2025 | Carvykti |
| Tersera Therapeutics LLC | $27.43 | 2025 | Quzyttir |
| Siemens Medical Solutions USA, INC. | $24.12 | 2023 | Varian Ethos Treatment Planning |
| Novartis Pharmaceuticals Corporation | $20.82 | 2021 | |
| Progenics Pharmaceuticals, INC. | $16.62 | 2022 | |
| Medtronic, INC. | $16.02 | 2025 | Synchromedii |
| Boston Scientific Corporation | $15.63 | 2019 | |
| Palette Life Sciences, INC. | $11.87 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Isaak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.